However, a subsequent larger phase II LCMC3 study reported that neoadjuvant atezolizumab for untreated stage IB–IIIB operable NSCLC without EGFR or ALK mutations allowed an MPR rate of only 20% (30/147; 95% CI: 14–28%) and a pathological complete response (pCR) rate of only 7% (10/147; 95% CI: 3–12%)8. The gene discussed is ALK; the disease is non-small cell lung carcinoma.